Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;26(8):1895-8.
doi: 10.1038/leu.2012.72. Epub 2012 Mar 19.

Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease

C Royo, A Navarro, G Clot, I Salaverria, E Giné, P Jares, D Colomer, A Wiestner, W H Wilson, M C Vegliante, V Fernandez, E M Hartmann, N Trim, W N Erber, S H Swerdlow, W Klapper, M J S Dyer, M Vargas-Pabón, G Ott, A Rosenwald, R Siebert, A López-Guillermo, E Campo, S Beà

Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease

C Royo et al. Leukemia. 2012 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors indicated no potential conflicts of interest.

Figures

Figure 1
Figure 1
Survival curves of MCL. (a) Kaplan-Meier estimates of overall survival for 59 MCL patients according to the high (hsMCL, n=42) or low (lsMCL, n=17) expression of the 3-gene signature. Two out of the 5 dead patients in the lsMCL group died of a MCL-unrelated cause but all patients in the hsMCL group died of the disease. (b) Kaplan-Meier estimates of overall survival for 53 MCL patients according to the presence of lymphadenopathy and the high or low 3-gene expression signature. Patients with low signature and no lymphadenopathies show a better overall survival than the remaining 3 groups. (c) Survival curves for patients with high 3-gene signature (hsMCL) according to 17p status (17p altered vs. 17p not altered); and (d) survival curves for patients with low 3-gene signature (lsMCL) according to 17p status (17p altered vs. 17p not altered).
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC; Lyon: 2008.
    1. Royo C, Salaverria I, Hartmann E, Rosenwald A, Campo E, Bea S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol. 2011;5:322–334. - PubMed
    1. Eve HE, Furtado MV, Hamon MD, Rule SA. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol. 2009;27:e189–e190. - PubMed
    1. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408–1418. - PubMed
    1. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209–1213. - PubMed

Publication types